However, DOACs are not recommended for patients with a history of thrombosis who are diagnosed with antiphospholipid syndrome, particularly those who are triple-positive (for lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2 glycoprotein I antibodies) and thus at an increased risk of recurrence. Here, APOH is linked to antiphospholipid syndrome.